Baseline characteristics of deliveries overall and by use of domperidone in the 6 months immediately postpartum*
| Characteristic | No. (%) of deliveries† | ||
|---|---|---|---|
| Overall n = 1 190 987 | Domperidone n = 137 401 | No domperidone n = 1 053 586 | |
| Age, yr, mean ± SE | 28.6 ± 0.6 | 29.6 ± 0.4 | 28.5 ± 0.6 |
| Obesity‡ | 22 549 (1.9) | 3221 (2.3) | 19 328 (1.8) |
| Alcohol-related disorders | 27 340 (2.3) | 2266 (1.7) | 25 074 (2.4) |
| Income quintile | |||
| 1 (lowest) | 267 188 (22.4) | 24 705 (18.0) | 242 483 (23.0) |
| 2 | 233 098 (19.6) | 25 919 (18.9) | 207 179 (19.7) |
| 3 | 218 305 (18.3) | 26 947 (19.6) | 191 358 (18.2) |
| 4 | 223 515 (18.8) | 28 496 (20.7) | 195 019 (18.5) |
| 5 (highest) | 177 454 (14.9) | 23 423 (17.1) | 154 031 (14.6) |
| Unknown | 71 427 (6.0) | 7911 (5.8) | 63 516 (6.0) |
| Comorbidities | |||
| Previous history of arrhythmia or conduction disorders | 28 582 (2.4) | 4047 (3.0) | 24 535 (2.3) |
| Any insertion of a pacemaker or defibrillator | 234 (< 0.1) | 28 (< 0.1) | 183 (< 0.1) |
| Hypertension | 66 828 (5.6) | 9658 (7.0) | 57 170 (5.4) |
| Cardiomyopathy | 1193 (0.1) | 139 (0.1) | 1054 (1.0) |
| Left ventricular hypertrophy | 159 (< 0.1) | 14 (< 0.1) | 143 (0.0) |
| Heart failure | 2435 (0.2) | 330 (0.2) | 2105 (0.2) |
| Ischemic heart disease | 12 384 (1.0) | 1956 (1.4) | 10 428 (1.0) |
| Valvular heart disease | 2620 (0.2) | 327 (0.2) | 2293 (0.2) |
| Diabetes | 65 651 (5.5) | 10 116 (7.4) | 55 535 (5.3) |
| Depression | 157 761 (13.3) | 20 421 (14.9) | 137 340 (13.0) |
| Pregnancy-related characteristics | |||
| Multifetal gestation | 22 008 (1.9) | 5547 (4.0) | 16 461 (1.6) |
| Parity ≥ 1 | |||
| No | 579 511 (48.7) | 87 614 (63.8) | 491 897 (46.7) |
| Yes | 611 025 (51.3) | 49 773 (36.2) | 561 252 (53.3) |
| Unknown | 451 (0.0) | 14 (0.0) | 437 (0.0) |
| Cesarean delivery | 332 987 (28.0) | 49 579 (36.1) | 283 408 (26.9) |
| Gestational age, wk, mean ± SE | 39 ± 0.2 | 38.6 ± 0.3 | 39.1 ± 0.2 |
| ≤ 37 | 128 950 (10.8) | 21 132 (15.4) | 107 818 (10.2) |
| 38–42 (inclusive) | 1 061 930 (89.2) | 116 262 (84.6) | 945 668 (89.8) |
| ≥ 43 | 107 (0.0) | 6 (0.0) | 100 (0.0) |
| Use of medications | |||
| Antiarrhythmic drugs | 26 731 (2.2) | 4456 (3.2) | 22 275 (2.1) |
| Statins | 2286 (0.2) | 366 (0.3) | 1920 (0.2) |
| Antihypertensive medications | 41 499 (3.5) | 6915 (5.0) | 34 584 (3.3) |
| Proton pump inhibitors | 63 432 (5.3) | 10 389 (7.6) | 53 043 (5.0) |
| Antipsychotic medications | 18 990 (1.6) | 2486 (1.8) | 16 504 (1.6) |
| Other medications with galactagogic effects | 32 607 (2.7) | 4652 (3.4) | 27 955 (2.7) |
| Drugs with known risk of QT prolongation | 294 860 (24.8) | 42 866 (31.2) | 251 994 (23.9) |
| Strong and moderate CYP3A4 inhibitors | 130 647 (11.0) | 18 051 (13.1) | 112 596 (10.7) |
Note: CYP3A4 = cytochrome P450 3A4, SE = standard error.
↵* Patients were permitted to contribute multiple observations to the study cohort.
↵† Unless stated otherwise.
↵‡ Defined using diagnostic codes for obesity (International Statistical Classification of Disease and Related Health Problems, 10th Revision code E66.x and International Classification of Diseases, 9th Revision code 278.0).